<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Carr T</submitter><funding>NIAID NIH HHS</funding><funding>NCI NIH HHS</funding><funding>National Institutes of Health</funding><pagination>845488</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8971981</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13</volume><pubmed_abstract>T lymphocyte acute lymphoblastic leukemia (T-ALL) is a heterogeneous disease affecting T cells at multiple stages of their development and is characterized by frequent genomic alterations. The transcription factor LEF1 is inactivated through mutation in a subset of T-ALL cases but elevated LEF1 expression and activating mutations have also been identified in this disease. Here we show, in a murine model of T-ALL arising due to &lt;i>E2a&lt;/i> inactivation, that the developmental timing of &lt;i>Lef1&lt;/i> mutation impacts its ability to function as a cooperative tumor suppressor or oncogene. T cell transformation in the presence of LEF1 allows leukemic cells to become addicted to its presence. In contrast, deletion prior to transformation both accelerates leukemogenesis and results in leukemic cells</pubmed_abstract><journal>Frontiers in immunology</journal><pubmed_title>Oncogenic and Tumor Suppressor Functions for Lymphoid Enhancer Factor 1 in &lt;i>E2a&lt;sup>-/-&lt;/sup>&lt;/i> T Acute Lymphoblastic Leukemia.</pubmed_title><pmcid>PMC8971981</pmcid><funding_grant_id>R01 AI079213</funding_grant_id><funding_grant_id>R21 AI096530</funding_grant_id><funding_grant_id>R21 AI119894</funding_grant_id><funding_grant_id>P30 CA014599</funding_grant_id><pubmed_authors>Xue HH</pubmed_authors><pubmed_authors>Carr T</pubmed_authors><pubmed_authors>Dias S</pubmed_authors><pubmed_authors>Sigvardsson M</pubmed_authors><pubmed_authors>Le Beau MM</pubmed_authors><pubmed_authors>Kee BL</pubmed_authors><pubmed_authors>McGregor S</pubmed_authors><pubmed_authors>Verykokakis M</pubmed_authors><pubmed_authors>Bartom ET</pubmed_authors></additional><is_claimable>false</is_claimable><name>Oncogenic and Tumor Suppressor Functions for Lymphoid Enhancer Factor 1 in &lt;i>E2a&lt;sup>-/-&lt;/sup>&lt;/i> T Acute Lymphoblastic Leukemia.</name><description>T lymphocyte acute lymphoblastic leukemia (T-ALL) is a heterogeneous disease affecting T cells at multiple stages of their development and is characterized by frequent genomic alterations. The transcription factor LEF1 is inactivated through mutation in a subset of T-ALL cases but elevated LEF1 expression and activating mutations have also been identified in this disease. Here we show, in a murine model of T-ALL arising due to &lt;i>E2a&lt;/i> inactivation, that the developmental timing of &lt;i>Lef1&lt;/i> mutation impacts its ability to function as a cooperative tumor suppressor or oncogene. T cell transformation in the presence of LEF1 allows leukemic cells to become addicted to its presence. In contrast, deletion prior to transformation both accelerates leukemogenesis and results in leukemic cells</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2026-04-08T18:06:55.955Z</modification><creation>2025-04-05T22:19:38.995Z</creation></dates><accession>S-EPMC8971981</accession><cross_references><pubmed>35371057</pubmed><doi>10.3389/fimmu.2022.845488</doi></cross_references></HashMap>